In a day of mixed news for Bristol-Myers Squibb (NYSE: BMY), the company revealed an upbeat second-quarter 2019 results statement, fighting earlier pre-market declines on the back of a trial failure in lung cancer.
The New York-based cancer specialist managed to increase second-quarter revenues to $6.3 billion, up 10% on the same period from 2018, and posted second-quarter earnings per share (EPS) of $0.87, following Generally Accepted Accounting Principles (GAAP).
The strong results were driven largely by robust sales for Eliquis (apixaban) and Opdivo (nivolumab) as well as a good performance across the portfolio. Results in the USA were particularly encouraging, with a revenue increase of 14%, to $3.7 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze